Document Detail

Have the renin-angiotensin-aldosterone system perturbations in cardiovascular disease been exhausted?
MedLine Citation:
PMID:  20827517     Owner:  NLM     Status:  MEDLINE    
The renin-angiotensin-aldosterone system (RAAS) plays an important role in blood pressure control and volume homeostasis. Inappropriate activation of the RAAS has been implicated in the pathogenesis of hypertension and related cardiovascular disease. Several classes of agents that block RAAS signaling have been shown to be effective antihypertensives and to have cardioprotective and renoprotective properties. Because blockade of the RAAS is incomplete with any of the currently available monotherapies, combinations of these agents have been tested and shown to provide additional clinical benefit in patients with hypertension and various forms of cardiovascular and renal disease.
Sulaf J Mansur; Fadi G Hage; Suzanne Oparil
Related Documents :
18698217 - Blood pressure outcome of adrenalectomy in patients with primary hyperaldosteronism wit...
6874387 - Factitious hypertension with mineralocorticoid excess in an infant.
19895757 - Aldosterone and cardiovascular risk.
11411757 - Aldosterone esters and the heart.
10826727 - Inactivation of listeria monocytogenes scott a on artificially contaminated frankfurter...
12897577 - Which endpoint: mean intraocular pressure or proportion of successful patients?
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current cardiology reports     Volume:  12     ISSN:  1534-3170     ISO Abbreviation:  Curr Cardiol Rep     Publication Date:  2010 Nov 
Date Detail:
Created Date:  2010-09-15     Completed Date:  2010-12-30     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100888969     Medline TA:  Curr Cardiol Rep     Country:  United States    
Other Details:
Languages:  eng     Pagination:  450-63     Citation Subset:  IM    
Jefferson Clinic PC, Birmingham, AL, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiotensin II Type 1 Receptor Blockers / pharmacology,  therapeutic use
Angiotensin-Converting Enzyme Inhibitors / pharmacology,  therapeutic use
Antihypertensive Agents / pharmacology,  therapeutic use
Cardiovascular Diseases / drug therapy*,  etiology,  physiopathology
Heart Failure / drug therapy,  etiology,  physiopathology
Hypertension / drug therapy,  etiology,  physiopathology
Kidney Failure, Chronic / drug therapy,  etiology,  physiopathology
Receptors, Mineralocorticoid / antagonists & inhibitors
Renin / antagonists & inhibitors,  drug effects,  physiology
Renin-Angiotensin System / drug effects*,  physiology
Reg. No./Substance:
0/Angiotensin II Type 1 Receptor Blockers; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Antihypertensive Agents; 0/Receptors, Mineralocorticoid; EC

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Spectroscopic and molecular modeling studies on the interaction between a fluorine-containing triazo...
Next Document:  Intentions to quit smoking: causal attribution, perceived illness severity, and event-related fear d...